Dimensional Fund Advisors
GALT icon

Dimensional Fund Advisors’s Galectin Therapeutics GALT Stock Holding History

Dimensional Fund Advisors’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,877
Closed -$19K – 3491
2022
Q1 		$19K Hold
11,877
– – ﹤0.01% 3501
2021
Q4 		$25K Hold
11,877
– – ﹤0.01% 3523
2021
Q3 		$46K Sell
11,877
-100
-0.8% -$339 ﹤0.01% 3478
2021
Q2 		$38K Hold
11,977
– – ﹤0.01% 3448
2021
Q1 		$26K Buy
+11,977
New +$26.8K ﹤0.01% 3404

Other funds holding GALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GWM
Geneos Wealth Management Englewood, Colorado $4.9B AUM 23.65% 1-Year Est. Return
AWS
Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CCB
Cutter & Co Brokerage Ballwin, Missouri $423M AUM 15.02% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Dimensional Fund Advisors's GALT Position: Q2 2022 in Review

Dimensional Fund Advisors sold out of Galectin Therapeutics (GALT) in Q2 2022, closing a stake of 11,877 shares — an estimated $19K sold.

Dimensional Fund Advisors first reported a position in GALT in Q1 2021 and held it in 5 quarters. The position peaked at $46K in Q3 2021. 60 funds tracked by Wall St. Rank hold GALT as of Q2 2022.

  • Dimensional Fund Advisors reported no remaining Galectin Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Dimensional Fund Advisors sold 11,877 Galectin Therapeutics shares in Q2 2022, an estimated $19K.
  • Dimensional Fund Advisors first reported a position in Galectin Therapeutics in Q1 2021 and held it in 5 quarters.
  • Dimensional Fund Advisors's Galectin Therapeutics position peaked at $46K in Q3 2021.
  • 60 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2022.

Based on Dimensional Fund Advisors's 13F filing for Q2 2022, filed 12 Aug 2022.